Ramipril

Ramipril is a long-acting angiotensin-converting-enzyme inhibitor, one of a group of medicines used for cardiovascular and kidney conditions ^[1][4]. Chemically it is an ester prodrug that is inactive until the body converts it; the liver enzyme carboxylesterase 1 hydrolyzes it into the active metabolite ramiprilat ^[4]. It was developed by the German firm Hoechst and reached medical use toward the end of the 1980s, later becoming available generically after its patent was invalidated ^[1].

The drug is prescribed for hypertension, congestive heart failure, and protection of the heart and kidneys in people at high cardiovascular risk ^[1][2]. In the large HOPE trial, ramipril significantly reduced the combined rate of heart attack, stroke, and cardiovascular death in high-risk patients who had no known heart failure ^[1]. Its MICRO-HOPE substudy found comparable benefits in people with diabetes, including a lower rate of overt kidney disease, an effect that appeared to exceed what blood-pressure lowering alone would predict ^[2]. The earlier AIRE study showed that starting ramipril in survivors of a heart attack who had signs of heart failure reduced deaths from any cause ^[3].

Ramipril is a prescription-only medicine in most countries and is supplied as oral capsules or tablets, sometimes combined with other blood-pressure agents ^[1][4]. Because its patent was later overturned for obviousness, numerous generic versions are now marketed ^[1].

Ramipril is prescription only and carries a boxed warning against use in pregnancy, where it can seriously harm or kill the fetus. A common and harmless but annoying effect is a persistent dry cough from bradykinin. More serious concerns are high potassium, low blood pressure especially after the first dose, worsening kidney function in people with narrowed kidney arteries, and rarely angioedema, a dangerous swelling of the face, lips or airway that needs emergency care. Avoid it with potassium supplements or potassium sparing diuretics, with the direct renin blocker aliskiren in diabetes, and be cautious with NSAIDs and lithium.

Ramipril inhibits angiotensin-converting enzyme, and the interactions that matter either raise potassium, drop pressure too far, or add to angioedema risk.

Potassium-sparing diuretics, potassium supplements, salt substitutes, trimethoprim and NSAIDs all combine with ramipril to produce hyperkalemia, since less aldosterone means less potassium excretion. NSAIDs additionally blunt the antihypertensive effect and, in a dehydrated or elderly patient also taking a diuretic, can precipitate acute kidney injury.

Angioedema is the interaction with the sharpest consequence. ACE inhibition already slows bradykinin breakdown; sacubitril inhibits neprilysin, another bradykinin-degrading enzyme, so the combination is contraindicated and the labelling requires a 36-hour gap when switching between them. mTOR inhibitors such as sirolimus and everolimus, and the DPP-4 inhibitors, also raise angioedema risk alongside ramipril.

Pairing ramipril with an angiotensin receptor blocker or with aliskiren gives hypotension, hyperkalemia and renal failure without outcome benefit. Ramipril also raises serum lithium and has caused lithium toxicity.

Checking a whole stack? Run it through interactions + stacks.

Ramipril is an angiotensin-converting-enzyme inhibitor developed by the German company Hoechst and introduced to major markets in the late 1980s under brand names including Altace and Tritace. Like other members of its class, it is administered as a prodrug that the body converts into its active form, ramiprilat, which blocks the enzyme responsible for generating the vasoconstrictor angiotensin II.

Its reputation was transformed by the landmark Heart Outcomes Prevention Evaluation (HOPE) study, reported in 2000, which enrolled thousands of high-risk patients and found that ramipril substantially reduced the combined risk of cardiovascular death, heart attack, and stroke, with especially striking benefits in people with diabetes. Because these gains exceeded what the modest blood-pressure reduction alone could explain, HOPE broadened the drug's use from hypertension and heart failure into cardiovascular risk prevention. Ramipril has long since become an inexpensive, widely prescribed generic medicine and appears among the most commonly dispensed cardiovascular drugs worldwide.

Ramipril is one of the most trusted and extensively validated ACE inhibitors, esteemed for evidence that reaches well beyond simple blood-pressure lowering. The HOPE trial gave it a durable reputation as a drug that protects the heart, brain, and kidneys in high-risk patients, and its benefit in people with diabetes is particularly valued. Physicians appreciate its once-daily dosing, low cost as a generic, and a large body of outcome data supporting its use in hypertension, heart failure, and after myocardial infarction.

Patients benefit from a medicine that is both affordable and backed by decades of experience. The class-typical dry cough, caused by its effect on bradykinin, is its most familiar drawback and occasionally leads to a switch, and, like all renin-angiotensin blockers, it requires care in pregnancy and with kidney function; even so, ramipril remains a cornerstone of cardiovascular protection.